Literature DB >> 8517842

Wegener's granulomatosis: clinical features and prognosis in 37 patients.

E Romas1, B F Murphy, A J d'Apice, J T Kennedy, J F Niall.   

Abstract

Thirty-seven patients (21 female, 16 male) with Wegener's granulomatosis (WG) were reviewed. Patients were followed for a mean six years after diagnosis; 14 were followed for more than seven years. The clinical features were similar to those in previous studies. In this series, only 13 patients (35%) had renal disease at presentation and the cumulative incidence of renal involvement was 51%. Thirty-one patients received treatment which included cyclophosphamide (CP). The case fatality rate of the six patients not treated with CP was 83% (five deaths). By contrast, all CP treated patients improved and 21 (68%) had complete remissions. Nine (29%) were in complete remission for a mean 4.9 years after discontinuing all treatment. Two were disease free for over ten years. The actuarial probability of survival for these patients was 97% at one year and 71% at ten years. Only three CP treated patients (10%) progressed to end-stage renal disease. The case fatality rate was 26% (eight patients) and sepsis was the cause of death in five. Fourteen patients (45%) treated with CP had at least one relapse of vasculitis and seven (23%) had multiple (two or more) relapses. These data indicate that CP is effective in inducing remissions and prolonging survival in patients with WG; however, relapses are frequent.

Entities:  

Mesh:

Year:  1993        PMID: 8517842     DOI: 10.1111/j.1445-5994.1993.tb01812.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  2 in total

1.  Wegener's granulomatosis: experience from a Brazilian tertiary center.

Authors:  Fernando Henrique Carlos de Souza; Ari Stiel Radu Halpern; Carmen Silvia Valente Barbas; Samuel Katsuyuki Shinjo
Journal:  Clin Rheumatol       Date:  2010-03-01       Impact factor: 2.980

2.  Granulomatous gastritis in Wegener's disease: differentiation from Crohn's disease supported by a positive test for antineutrophil antibodies.

Authors:  B Temmesfeld-Wollbrueck; C Heinrichs; A Szalay; W Seeger
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.